Biotek-snakken — Juni 2020
-
ENLV er relativt nye og har gang i mange spændende ting indenfor immuneterapi. Rejse i Feb. $24 M i direct offering af to omgange til kurs $8 og handler nu i $6. Godt sted at starte med DD er deres årsrapport https://dd7pmep5szm19.cloudfront.net/2380/0001213900-20-010632.pdf
-
Nu vi er ved de her small cap biotech så har Cellectar fået styr på deres funding ind i 2023. Sikret patent i EU og fået FDA Fast Track Designation i LPL/WM. Der afvendes data fra deres 2 cycle dose expansion cohort 2H-20. Seneste clinical data call https://viavid.webcasts.com/viewer/event.jsp?ei=1278219&tp_key=119af7bc64
-
Der kommer snart lidt prækliniske data for deres PRGN-3005 (UltraCAR-T),
og data i slutningen af året - men det er jo nok mest spekulation pt. Og så var den nok kommet ret langt ned. Denne kan give et bud på det vi ser nu. https://finance.yahoo.com/news/billionaire-israel-englander-bets-3-133506340.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
Den er jeg også lidt spændt på....old school CAR-T